KDR and neoplasm: Sorafenib, a multi-target tyrosine kinase inhibitor, reduces tumor angiogenesis by inhibiting Raf kinase, VEGFR, and PDGFR, but its anti-angiogenic effects can lead to decreased retinal blood flow and vessel narrowing, increasing RVO risk (Liu et al., 2006).